6月5日 - ** 基因疗法开发商Regenxbio RGNX.O股价盘前上涨2.7%,报10.35美元
** RGNX称其用于治疗杜氏肌营养不良症的实验性基因疗法RGX-202(DMD) 在早期研究中没有发现严重不良事件,是安全的
** 杜氏肌营养不良症会导致骨骼肌和心肌无力,并随着时间的推移迅速恶化
** 公司表示,研究数据有望支持 2026 年中期加速审批的监管途径
** 预计在 2026 年上半年分享进一步的研究数据
** 截至上次收盘,RGNX年累计上涨30.4
(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.